N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/89710 |
Resumo: | Background: Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC. Results: NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB. Conclusions: Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment. |
id |
UFRGS-2_d615f49ad09b5e24b84c4140867e5b6f |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/89710 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Kretzmann, Nelson AlexandreChiela, Eduardo Cremonese FilippiMatte, Ursula da SilveiraMarroni, Norma Anair PossaMarroni, Claudio Augusto2014-03-26T01:51:10Z20121476-5926http://hdl.handle.net/10183/89710000910724Background: Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC. Results: NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB. Conclusions: Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.application/pdfengComparative hepatology. London. Vol. 11 (2012), 9 p.AcetilcisteínaInterferon alfaNeoplasias hepáticasN-acetylcysteineInterferon alphaNF-kBLiver cancer cellsN-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cellsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000910724.pdf000910724.pdfTexto completo (inglês)application/pdf1594330http://www.lume.ufrgs.br/bitstream/10183/89710/1/000910724.pdf88e129670ad3376d738946aad96ba661MD51TEXT000910724.pdf.txt000910724.pdf.txtExtracted Texttext/plain38683http://www.lume.ufrgs.br/bitstream/10183/89710/2/000910724.pdf.txt25301714f484605d18870ff994a256a8MD52THUMBNAIL000910724.pdf.jpg000910724.pdf.jpgGenerated Thumbnailimage/jpeg1968http://www.lume.ufrgs.br/bitstream/10183/89710/3/000910724.pdf.jpgf4b8bd1f4baaa3afa512c1c9c19b5bcbMD5310183/897102018-10-18 08:56:37.439oai:www.lume.ufrgs.br:10183/89710Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2018-10-18T11:56:37Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
title |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
spellingShingle |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells Kretzmann, Nelson Alexandre Acetilcisteína Interferon alfa Neoplasias hepáticas N-acetylcysteine Interferon alpha NF-kB Liver cancer cells |
title_short |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
title_full |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
title_fullStr |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
title_full_unstemmed |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
title_sort |
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells |
author |
Kretzmann, Nelson Alexandre |
author_facet |
Kretzmann, Nelson Alexandre Chiela, Eduardo Cremonese Filippi Matte, Ursula da Silveira Marroni, Norma Anair Possa Marroni, Claudio Augusto |
author_role |
author |
author2 |
Chiela, Eduardo Cremonese Filippi Matte, Ursula da Silveira Marroni, Norma Anair Possa Marroni, Claudio Augusto |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Kretzmann, Nelson Alexandre Chiela, Eduardo Cremonese Filippi Matte, Ursula da Silveira Marroni, Norma Anair Possa Marroni, Claudio Augusto |
dc.subject.por.fl_str_mv |
Acetilcisteína Interferon alfa Neoplasias hepáticas |
topic |
Acetilcisteína Interferon alfa Neoplasias hepáticas N-acetylcysteine Interferon alpha NF-kB Liver cancer cells |
dc.subject.eng.fl_str_mv |
N-acetylcysteine Interferon alpha NF-kB Liver cancer cells |
description |
Background: Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC. Results: NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB. Conclusions: Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2014-03-26T01:51:10Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/89710 |
dc.identifier.issn.pt_BR.fl_str_mv |
1476-5926 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000910724 |
identifier_str_mv |
1476-5926 000910724 |
url |
http://hdl.handle.net/10183/89710 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Comparative hepatology. London. Vol. 11 (2012), 9 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/89710/1/000910724.pdf http://www.lume.ufrgs.br/bitstream/10183/89710/2/000910724.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/89710/3/000910724.pdf.jpg |
bitstream.checksum.fl_str_mv |
88e129670ad3376d738946aad96ba661 25301714f484605d18870ff994a256a8 f4b8bd1f4baaa3afa512c1c9c19b5bcb |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224828878848000 |